Dacetuzumab

DB12589InvestigationalProtein Based Therapies

Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces...

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.Curator reviewed
Code names: SGN-40

Resolves to

Compound

UNIIUT59FF4T5XCAS880486-59-9

Targets

P25942CD40

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dacetuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account